World Health Organization, “Mortality Country Fact Sheet,” 2006. http://www.who.int/whosis/mort/profiles/mort_searo_ lka_srilanka.pdf
 NCCAM, National Institutes of Health, “Questions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Artery Disease,” 2004. http://nccam.nih.gov/ health/chelation/q-and-a.htm
 G. Kindness and J. P. Frackleton, “Effect of Ethylene Diamine Tetra Acetic Acid (EDTA) and Platelet Aggregation in Human Blood,” Journal of Advancement in Medicine, Vol. 2, No. 4, 1989, pp. 519-530.
 L. Chappell and J. P. Stahl, “The Correlation between EDTA Chelation Therapy and Improvement in Cardiovascular Function: A Meta Analysis,” Journal of Advancement in Medicine, Vol. 6, No. 3, 1993, pp. 139-160.
 M. L. Knudtson, D. G. Wyse, P. D. Galbraith, R. Brant, K. Hildebrand, D. Paterson and D. Richardson, “Chelation Therapy for Ischemic Heart Disease: A Randomized Controlled Trial,” Journal of the American Medical Association, Vol. 287, No. 4, 23-30 January 2002, pp. 481- 486.
 “Critique of the Calgary PATCH EDTA Chelation Study,” Adapted from a report by Croft Woodruff in Canada, 2007. http://www.drcranton.com/calgarystudy.htm
 E. M. Cranton, “Protocol of the American College of Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy”. Journal of Advancement in Medicine, Vol. 2, No. 1-2, 1989, pp 269- 305.
 J. S. Shrihari, A. Roy, D. Prabhakaran and K. S. Reddy, “Role of EDTA Chelation Therapy in Cardiovascular Diseases,” National Medical Journal of India, Vol. 19, No. 1, January-February 2006, pp. 24-26.
 P. M. Kidd, “Integrative Cardiac Revitalization: Bypass Surgery, Angioplasty, and Chelation. Benefits, Risks, and Limitations,” Alternative Medicine Review, Vol. 3, No. 1, February 1998, pp. 4-17.
 H. Quan, W. A. Ghali, M. J. Verhoef, C. M. Norris, P. D. Galbraith and M. L. Knudtson, “Use of Chelation Therapy after Coronary Angiography,” American Journal of Medicine, Vol. 111, No. 9, 15 December 2001, pp. 686- 691.
 E. W. McDonagh, C. J. Rudolph, E. Cheraskin and D. G. Wussow, “The Effect of EDTA Chelation and Supportive Multivitamin/Trace Mineral Supplementation with and without Physical Activity upon Systolic Blood Pressure” Journal of Orthomolecular Psychiatry, Vol. 13, 1984, pp. 1-9.
 E. M. Cranton and J. P. Frackelton, “Current Status of EDTA Chelation Therapy in Occlusive Arterial Disease,” 2001. http://www.drcranton.com/chelation/emcjpf.htm
 R. Yamamoto, T. Kawamura, K. Wakai, Y. Ichihara, T. Anno and Y. Mizuno, “Favorable Life-Style Modification and Attenuation of Cardiovascular Risk Factors,” Japanese Circulation Society, Vol. 63, No. 3, March 1999, pp. 184-188.
 “EDTA Chelation: The Real ‘Miracle’ Therapy for Vascular Diseases,” Journal of Life Enhancement, 1997. http:// www.life-enhancement.com/article_template.asp?ID=78
 M. Elmer and E. M. Cranton, “Protocol of the American College for Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy,” Journal of Advancement in Medicine, Vol. 2, No. 1-2, 1989, pp. 269-303.